What is the primary purpose of this acquisition for Gilead Sciences?

The primary purpose of this acquisition is for Gilead Sciences to significantly expand its oncology pipeline and establish a strong presence in the cutting-edge field of cell therapy, particularly CAR T-cell therapies, which represent a high-growth area in cancer treatment.

What is the financial value of this transaction?

The transaction values Kite Pharma at $180.00 per share in cash, which, based on the typical outstanding shares at the time, amounted to a total transaction value of approximately $11.9 billion.

What are the key conditions that must be met for the acquisition to be completed?

Key conditions include the successful tender of a majority of Kite Pharma's outstanding shares in the tender offer, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act), and the absence of any governmental orders or laws prohibiting the transaction.

What is the role of Kite Pharma's board of directors regarding alternative offers?

Kite Pharma's board of directors is subject to 'no-shop' restrictions, meaning they generally cannot solicit alternative acquisition proposals. However, they may engage with third parties regarding alternative proposals under specific circumstances if the board determines that such a proposal could lead to a 'Superior Offer' and failing to do so would be inconsistent with their fiduciary duties.

GILD 8-K: Material Agreements

Summary

Gilead Sciences, Inc. (GILD) has announced a significant development through an 8-K filing on August 28, 2017, detailing their entry into a definitive agreement to acquire Kite Pharma, Inc. This strategic move involves a tender offer to acquire all outstanding shares of Kite Pharma for $180.00 per share in cash, representing a total transaction value of approximately $11.9 billion. The acquisition is a substantial investment aimed at bolstering Gilead's presence in the rapidly growing field of cell therapy. The acquisition positions Gilead to leverage Kite Pharma's expertise and pipeline in oncology, particularly its chimeric antigen receptor (CAR) T-cell therapies. This move signifies Gilead's commitment to expanding its therapeutic reach beyond its established antiviral franchise and into innovative, high-potential areas of medicine. Investors should closely monitor the tender offer process, regulatory approvals, and the integration of Kite Pharma's assets to gauge the long-term strategic and financial impact of this acquisition.

Key Highlights

1Gilead Sciences entered into an Agreement and Plan of Merger with Kite Pharma, Inc. on August 27, 2017.
2Gilead will commence a tender offer to acquire all outstanding shares of Kite Pharma for $180.00 per share in cash.
3The total transaction value is approximately $11.9 billion (based on an implied share count for Kite Pharma's outstanding shares).
4The acquisition is a strategic move by Gilead to enhance its oncology portfolio, particularly in cell therapy.
5The transaction is subject to customary closing conditions, including the tender of a majority of Kite Pharma's shares and regulatory approvals (e.g., HSR Act).
6Kite Pharma has agreed to customary 'no-shop' provisions, with a termination fee of $356 million payable under certain circumstances.
7A joint press release announcing the merger agreement was issued on August 28, 2017.

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Aug 28, 2017)

Summary

Key Highlights

Frequently Asked Questions